Wave Life Sciences
About: WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Employees: 288
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
962% more call options, than puts
Call options by funds: $3.25M | Put options by funds: $306K
108% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 39
3.17% more ownership
Funds ownership: 85.54% [Q1] → 88.71% (+3.17%) [Q2]
11% less funds holding
Funds holding: 195 [Q1] → 173 (-22) [Q2]
15% less capital invested
Capital invested by funds: $1.06B [Q1] → $897M (-$164M) [Q2]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]
40% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 40
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Canaccord Genuity Whitney Ijem | 91%upside $19 | Buy Initiated | 4 Aug 2025 |
Wells Fargo Tiago Fauth | 111%upside $21 | Overweight Maintained | 31 Jul 2025 |
Oppenheimer Cheng Li | 141%upside $24 | Outperform Initiated | 28 Jul 2025 |
Citigroup Samantha Semenkow | 61%upside $16 | Buy Initiated | 16 Jul 2025 |
Wedbush Yun Zhong | 81%upside $18 | Outperform Reiterated | 23 Jun 2025 |
Financial journalist opinion
Based on 4 articles about WVE published over the past 30 days
